MedTrace Logo

Suprachoroidal Triamcinolone Acetonide in Harada's Retinal Detachment

NCT05031143 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-10-07

No results posted yet for this study

Summary

Suprachoroidal injection, a novel technique for delivering ocular therapies, may facilitate targeted therapeutic delivery to the choroidal and retinal structures than intravitreal injection

Conditions

  • Vogt Koyanagi Harada Disease

Interventions

DRUG

Suprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH disease

Suprachoroidal steroid injection for management of serous retinal detachment in VKH disease

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Ahmed Abdelshafy, MD · Benha University, faculty of medicine

  • Marwa Abdelshafy, MD · Benha University, faculty of medicine

  • Mohamed Anany, MD · Benha University, faculty of medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
47 Years
Max Age
52 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2021-02-20
Completion
2021-08-24

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05031143 on ClinicalTrials.gov